{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:27:56Z","timestamp":1792520876018,"version":"4.5.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T00:00:00Z","timestamp":1379376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10585-013-9615-4","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T10:24:50Z","timestamp":1379327090000},"page":"135-147","source":"Crossref","is-referenced-by-count":54,"title":["Metastasis of ovarian cancer is mediated by kallikrein related peptidases"],"prefix":"10.1007","volume":"31","author":[{"given":"Ying","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Loessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Irving-Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Nicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,17]]},"reference":[{"key":"9615_CR1","volume-title":"cancer","author":"AIHW","year":"2010","unstructured":"AIHW (2010) Ovarian cancer in Australia: an overview. cancer. Australian Institute of Health and Welfare, Canberra"},{"key":"9615_CR2","unstructured":"Cancer-Research-UK., 2011 Ovarian cancer survival statistics"},{"key":"9615_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63:11\u201330","journal-title":"CA Cancer J Clin"},{"key":"9615_CR4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","volume":"7","author":"DS Tan","year":"2006","unstructured":"Tan DS, Agarwal R, Kaye SB (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7:925\u2013934","journal-title":"Lancet Oncol"},{"key":"9615_CR5","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"9615_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","volume":"9","author":"RC Bast Jr","year":"2009","unstructured":"Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415\u2013428","journal-title":"Nat Rev Cancer"},{"key":"9615_CR7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15\u201336","journal-title":"CA Cancer J Clin"},{"key":"9615_CR8","first-page":"3","volume-title":"Cancer treatment and research in \u201cOvarian cancer\u201d","author":"DA Fishman","year":"2002","unstructured":"Fishman DA, Borzorgi K (2002) Cancer treatment and research in \u201cOvarian cancer\u201d. Kluwer, Boston, pp 3\u201328"},{"key":"9615_CR9","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1371\/journal.pone.0018872","volume":"6","author":"Y Kwon","year":"2011","unstructured":"Kwon Y, Cukierman E, Godwin AK (2011) Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration\/invasion. PLoS One 6:18872","journal-title":"PLoS One"},{"key":"9615_CR10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2003.11.011","volume":"92","author":"PL Torng","year":"2004","unstructured":"Torng PL, Mao TL, Chan WY, Huang SC, Lin CT (2004) Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 92:559\u2013567","journal-title":"Gynecol Oncol"},{"key":"9615_CR11","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-07-5046","volume":"68","author":"KD Cowden Dahl","year":"2008","unstructured":"Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, Stack MS, Hudson LG (2008) Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 68:4606\u20134613","journal-title":"Cancer Res"},{"key":"9615_CR12","first-page":"2223","volume":"63","author":"GM Yousef","year":"2003","unstructured":"Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63:2223\u20132227","journal-title":"Cancer Res"},{"key":"9615_CR13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10408360490471931","volume":"41","author":"JA Clements","year":"2004","unstructured":"Clements JA, Willemsen NM, Myers M, Dong Y (2004) The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 41:265\u2013312","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9615_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","volume":"211","author":"Y Lee","year":"2007","unstructured":"Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26\u201335","journal-title":"J Pathol"},{"key":"9615_CR15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451\u2013456","journal-title":"J Pathol"},{"key":"9615_CR16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2559.2009.03237.x","volume":"54","author":"JM Piek","year":"2009","unstructured":"Piek JM, Verheijen RH, van Diest PJ (2009) Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 54:494\u2013495","journal-title":"Histopathology"},{"key":"9615_CR17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34:433\u2013443","journal-title":"Am J Surg Pathol"},{"key":"9615_CR18","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"M Shih Ie","year":"2004","unstructured":"Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511\u20131518","journal-title":"Am J Pathol"},{"key":"9615_CR19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484\u2013486","journal-title":"J Natl Cancer Inst"},{"key":"9615_CR20","first-page":"1489","volume":"53","author":"SC Mok","year":"1993","unstructured":"Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53:1489\u20131492","journal-title":"Cancer Res"},{"key":"9615_CR21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.1521","volume":"202","author":"NL Sieben","year":"2004","unstructured":"Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202:336\u2013340","journal-title":"J Pathol"},{"key":"9615_CR22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014shifting the paradigm. Hum Pathol 42:918\u2013931","journal-title":"Hum Pathol"},{"key":"9615_CR23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","volume":"10","author":"DD Bowtell","year":"2010","unstructured":"Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10:803\u2013808","journal-title":"Nat Rev Cancer"},{"key":"9615_CR24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"RN Tcga","year":"2011","unstructured":"Tcga RN (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609\u2013615","journal-title":"Nature"},{"key":"9615_CR25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/978-1-4757-3587-1_16","volume-title":"Cancer treatment and research: ovarian cancer","author":"S Ghosh","year":"2002","unstructured":"Ghosh S, Wu Y, Stack (2002) Ovarian Cancer-associated proteinases. In: Stack, Fishman DA (eds) Cancer treatment and research: ovarian cancer. Kluwer, Boston, pp 331\u2013354"},{"key":"9615_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1996.0106","volume":"61","author":"LE Puls","year":"1996","unstructured":"Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H (1996) The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 61:109\u2013112","journal-title":"Gynecol Oncol"},{"key":"9615_CR27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13:273\u2013282","journal-title":"Nat Rev Cancer"},{"key":"9615_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","volume":"113","author":"K Shield","year":"2009","unstructured":"Shield K, Ackland ML, Ahmed N, Rice GE (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:143\u2013148","journal-title":"Gynecol Oncol"},{"key":"9615_CR29","doi-asserted-by":"crossref","first-page":"46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2012) Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7:46858","journal-title":"PLoS One"},{"key":"9615_CR30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/geno.2000.6490","volume":"73","author":"JD Hooper","year":"2001","unstructured":"Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA (2001) Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 73:117\u2013122","journal-title":"Genomics"},{"key":"9615_CR31","doi-asserted-by":"crossref","first-page":"23210","DOI":"10.1074\/jbc.274.33.23210","volume":"274","author":"SA Stephenson","year":"1999","unstructured":"Stephenson SA, Verity K, Ashworth LK, Clements JA (1999) Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 274:23210\u201323214","journal-title":"J Biol Chem"},{"key":"9615_CR32","doi-asserted-by":"crossref","first-page":"37397","DOI":"10.1074\/jbc.M004525200","volume":"275","author":"TJ Harvey","year":"2000","unstructured":"Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA (2000) Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 275:37397\u201337406","journal-title":"J Biol Chem"},{"key":"9615_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/bbrc.2000.3448","volume":"276","author":"GM Yousef","year":"2000","unstructured":"Yousef GM, Chang A, Scorilas A, Diamandis EP (2000) Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 276:125\u2013133","journal-title":"Biochem Biophys Res Commun"},{"key":"9615_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-1119(00)00382-6","volume":"257","author":"L Gan","year":"2000","unstructured":"Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J, Moss P, Paeper B, Wang K (2000) Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene 257:119\u2013130","journal-title":"Gene"},{"key":"9615_CR35","first-page":"243","volume":"387","author":"A Lundwall","year":"2006","unstructured":"Lundwall A, Clauss A, Olsson AY (2006) Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors. Biol Chem 387:243\u2013249","journal-title":"Biol Chem"},{"key":"9615_CR36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1515\/BC.2008.075","volume":"389","author":"M Debela","year":"2008","unstructured":"Debela M, Beaufort N, Magdolen V, Schechter NM, Craik CS, Schmitt M, Bode W, Goettig P (2008) Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 389:623\u2013632","journal-title":"Biol Chem"},{"key":"9615_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1515\/BC.2009.026","volume":"390","author":"H Yoon","year":"2009","unstructured":"Yoon H, Blaber SI, Debela M, Goettig P, Scarisbrick IA, Blaber M (2009) A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 15. Biol Chem 390:373\u2013377","journal-title":"Biol Chem"},{"key":"9615_CR38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/er.2009-0034","volume":"31","author":"MG Lawrence","year":"2010","unstructured":"Lawrence MG, Lai J, Clements JA (2010) Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 31:407\u2013446","journal-title":"Endocr Rev"},{"key":"9615_CR39","doi-asserted-by":"crossref","first-page":"32989","DOI":"10.1074\/jbc.R109.027946","volume":"284","author":"G Sotiropoulou","year":"2009","unstructured":"Sotiropoulou G, Pampalakis G, Diamandis EP (2009) Functional roles of human kallikrein-related peptidases. J Biol Chem 284:32989\u201332994","journal-title":"J Biol Chem"},{"key":"9615_CR40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1474","volume":"4","author":"CA Borgono","year":"2004","unstructured":"Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876\u2013890","journal-title":"Nat Rev Cancer"},{"key":"9615_CR41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/hsz-2012-0249","volume":"394","author":"H Yoon","year":"2013","unstructured":"Yoon H, Blaber SI, Li W, Scarisbrick IA, Blaber M (2013) Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases. Biol Chem 394:137\u2013147","journal-title":"Biol Chem"},{"key":"9615_CR42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0167-4838(99)00284-8","volume":"1477","author":"M Laskowski","year":"2000","unstructured":"Laskowski M, Qasim MA (2000) What can the structures of enzyme-inhibitor complexes tell us about the structures of enzyme substrate complexes? Biochim Biophys Acta 1477:324\u2013337","journal-title":"Biochim Biophys Acta"},{"key":"9615_CR43","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.biochi.2010.06.022","volume":"92","author":"P Goettig","year":"2010","unstructured":"Goettig P, Magdolen V, Brandstetter H (2010) Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie 92:1546\u20131567","journal-title":"Biochimie"},{"key":"9615_CR44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chembiol.2009.05.008","volume":"16","author":"JE Swedberg","year":"2009","unstructured":"Swedberg JE, de Veer SJ, Harris JM (2009) Natural and engineered kallikrein inhibitors: an emerging pharmacopeia. Biol Chem 16:433\u2013443","journal-title":"Biol Chem"},{"key":"9615_CR45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.chembiol.2009.05.008","volume":"16","author":"JE Swedberg","year":"2009","unstructured":"Swedberg JE, Nigon LV, Reid JC, de Veer SJ, Walpole CM, Stephens CR, Walsh TP, Takayama TK, Hooper JD, Clements JA, Buckle AM, Harris JM (2009) Substrate-guided design of a potent and selective kallikrein-related peptidase inhibitor for kallikrein 4. Chem Biol 16:633\u2013643","journal-title":"Chem Biol"},{"key":"9615_CR46","doi-asserted-by":"crossref","first-page":"19302","DOI":"10.1371\/journal.pone.0019302","volume":"6","author":"JE Swedberg","year":"2011","unstructured":"Swedberg JE, de Veer SJ, Sit KC, Reboul CF, Buckle AM, Harris JM (2011) Mastering the canonical loop of serine protease inhibitors: enhancing potency by optimising the internal hydrogen bond network. PLoS One 6:19302","journal-title":"PLoS One"},{"key":"9615_CR47","author":"SJ de Veer","year":"2013","unstructured":"de Veer SJ, Ukolova SS, Munro CA, Swedberg JE, Buckle AM, Harris JM (2013) Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1. Biopolymers. doi: 10.1002\/peps.22231","journal-title":"Biopolymers"},{"key":"9615_CR48","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1373\/clinchem.2007.088104","volume":"53","author":"JL Shaw","year":"2007","unstructured":"Shaw JL, Diamandis EP (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53:1423\u20131432","journal-title":"Clin Chem"},{"key":"9615_CR49","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815\u20132825","journal-title":"Cancer Res"},{"key":"9615_CR50","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1210\/jcem.86.5.7625","volume":"86","author":"SA Myers","year":"2001","unstructured":"Myers SA, Clements JA (2001) Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line. J Clin Endocrinol Metab 86:2323\u20132326","journal-title":"J Clin Endocrinol Metab"},{"key":"9615_CR51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/1541-7786.MCR-08-0218","volume":"7","author":"J Lai","year":"2009","unstructured":"Lai J, Myers SA, Lawrence MG, Odorico DM, Clements JA (2009) Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol Cancer Res 7:129\u2013141","journal-title":"Mol Cancer Res"},{"key":"9615_CR52","first-page":"2363","volume":"7","author":"Y Dong","year":"2001","unstructured":"Dong Y, Kaushal A, Bui L, Chu S, Fuller PJ, Nicklin J, Samaratunga H, Clements JA (2001) Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7:2363\u20132371","journal-title":"Clin Cancer Res"},{"key":"9615_CR53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1568016052773351","volume":"3","author":"S Marcondes","year":"2005","unstructured":"Marcondes S, Antunes E (2005) The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr Med Chem Cardiovasc Hematol Agents 3:33\u201344","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"9615_CR54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/10454411990100040101","volume":"10","author":"JD Bartlett","year":"1999","unstructured":"Bartlett JD, Simmer JP, Ryu OH, Fincham AG, Hu CC, Zhang C, Qian Q (1999) Proteinases in developing dental enamel: characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. Crit Rev Oral Biol Med 10:425\u2013441","journal-title":"Crit Rev Oral Biol Med"},{"key":"9615_CR55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0722.2006.00341.x","volume":"114","author":"Y Yamakoshi","year":"2006","unstructured":"Yamakoshi Y, Hu JC, Fukae M, Yamakoshi F, Simmer JP (2006) How do enamelysin and kallikrein 4 process the 32-kDa enamelin? Eur J Oral Sci 114:379\u2013380","journal-title":"Eur J Oral Sci"},{"key":"9615_CR56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/jmg.2003.017657","volume":"41","author":"PS Hart","year":"2004","unstructured":"Hart PS, Hart TC, Michalec MD, Ryu OH, Simmons D, Hong S, Wright JT (2004) Mutation in kallikrein 4 causes autosomal recessive hypomaturation amelogenesis imperfecta. J Med Genet 41:545\u2013549","journal-title":"J Med Genet"},{"key":"9615_CR57","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.jid.5700675","volume":"127","author":"C Becker-Pauly","year":"2007","unstructured":"Becker-Pauly C, Howel M, Walker T, Vlad A, Aufenvenne K, Oji V, Lottaz D, Sterchi EE, Debela M, Magdolen V, Traupe H, Stocker W (2007) The alpha and beta subunits of the metalloprotease meprin are expressed in separate layers of human epidermis, revealing different functions in keratinocyte proliferation and differentiation. J Invest Dermatol 127:1115\u20131125","journal-title":"J Invest Dermatol"},{"key":"9615_CR58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1515\/bc.2010.023","volume":"391","author":"A Ohler","year":"2010","unstructured":"Ohler A, Debela M, Wagner S, Magdolen V, Becker-Pauly C (2010) Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol Chem 391:455\u2013460","journal-title":"Biol Chem"},{"key":"9615_CR59","doi-asserted-by":"crossref","first-page":"20292","DOI":"10.1074\/jbc.M100201200","volume":"276","author":"M Simon","year":"2001","unstructured":"Simon M, Jonca N, Guerrin M, Haftek M, Bernard D, Caubet C, Egelrud T, Schmidt R, Serre G (2001) Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem 276:20292\u201320299","journal-title":"J Biol Chem"},{"key":"9615_CR60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.0022-202X.2004.23547.x","volume":"124","author":"M Brattsand","year":"2005","unstructured":"Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T (2005) A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 124:198\u2013203","journal-title":"J Invest Dermatol"},{"key":"9615_CR61","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.0022-202X.2004.22512.x","volume":"122","author":"C Caubet","year":"2004","unstructured":"Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G (2004) Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE\/KLK5\/hK5 and SCCE\/KLK7\/hK7. J Invest Dermatol 122:1235\u20131244","journal-title":"J Invest Dermatol"},{"key":"9615_CR62","doi-asserted-by":"crossref","first-page":"25135","DOI":"10.1074\/jbc.272.40.25135","volume":"272","author":"SP Little","year":"1997","unstructured":"Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM (1997) Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer\u2019s disease brain. J Biol Chem 272:25135\u201325142","journal-title":"J Biol Chem"},{"key":"9615_CR63","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0006-291X(03)01271-3","volume":"307","author":"A Magklara","year":"2003","unstructured":"Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, Diamandis EP (2003) Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 307:948\u2013955","journal-title":"Biochem Biophys Res Commun"},{"key":"9615_CR64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1440-1819.2000.00731.x","volume":"54","author":"K Ogawa","year":"2000","unstructured":"Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N (2000) Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer\u2019s disease and Parkinson\u2019s disease. Psychiatry Clin Neurosci 54:419\u2013426","journal-title":"Psychiatry Clin Neurosci"},{"key":"9615_CR65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1750-3639.2012.00577.x","volume":"22","author":"IA Scarisbrick","year":"2012","unstructured":"Scarisbrick IA, Yoon H, Panos M, Larson N, Blaber SI, Blaber M, Rodriguez M (2012) Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol 22:709\u2013722","journal-title":"Brain Pathol"},{"key":"9615_CR66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8:268\u2013278","journal-title":"Nat Rev Cancer"},{"key":"9615_CR67","first-page":"1046","volume":"75","author":"P Cohen","year":"1992","unstructured":"Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046\u20131053","journal-title":"J Clin Endocrinol Metab"},{"key":"9615_CR68","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1046\/j.1432-1327.2001.02185.x","volume":"268","author":"S Rehault","year":"2001","unstructured":"Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T (2001) Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268:2960\u20132968","journal-title":"Eur J Biochem"},{"key":"9615_CR69","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.bbamcr.2011.05.007","volume":"1813","author":"VC Ramani","year":"2011","unstructured":"Ramani VC, Kaushal GP, Haun RS (2011) Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim Biophys Acta 1813:1525\u20131531","journal-title":"Biochim Biophys Acta"},{"key":"9615_CR70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/BC.2006.029","volume":"387","author":"N Beaufort","year":"2006","unstructured":"Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, Schmitt M, Pidard D, Magdolen V (2006) Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem 387:217\u2013222","journal-title":"Biol Chem"},{"key":"9615_CR71","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1586\/erm.10.71","volume":"10","author":"M Schmitt","year":"2010","unstructured":"Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brunner N, Foekens J, Harbeck N (2010) Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 10:1051\u20131067","journal-title":"Expert Rev Mol Diagn"},{"key":"9615_CR72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-59349-9_4","volume":"162","author":"V Magdolen","year":"2003","unstructured":"Magdolen V, Kruger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U, Schmitt M (2003) Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Recent Results Cancer Res 162:43\u201363","journal-title":"Recent Results Cancer Res"},{"key":"9615_CR73","doi-asserted-by":"crossref","first-page":"32095","DOI":"10.1074\/jbc.M513138200","volume":"281","author":"K Oikonomopoulou","year":"2006","unstructured":"Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD (2006) Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281:32095\u201332112","journal-title":"J Biol Chem"},{"key":"9615_CR74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1515\/BC.2008.078","volume":"389","author":"AJ Ramsay","year":"2008","unstructured":"Ramsay AJ, Reid JC, Adams MN, Samaratunga H, Dong Y, Clements JA, Hooper JD (2008) Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem 389:653\u2013668","journal-title":"Biol Chem"},{"key":"9615_CR75","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.yexcr.2009.10.022","volume":"316","author":"L Gao","year":"2010","unstructured":"Gao L, Chao L, Chao J (2010) A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res 316:376\u2013389","journal-title":"Exp Cell Res"},{"key":"9615_CR76","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1074\/jbc.M709493200","volume":"283","author":"AJ Ramsay","year":"2008","unstructured":"Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, Hooper JD (2008) Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem 283:12293\u201312304","journal-title":"J Biol Chem"},{"key":"9615_CR77","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1158\/0008-5472.CAN-03-2025","volume":"64","author":"Z Xi","year":"2004","unstructured":"Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F (2004) Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64:2365\u20132370","journal-title":"Cancer Res"},{"key":"9615_CR78","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/cncr.22606","volume":"109","author":"SK Johnson","year":"2007","unstructured":"Johnson SK, Ramani VC, Hennings L, Haun RS (2007) Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 109:1811\u20131820","journal-title":"Cancer"},{"key":"9615_CR79","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MPA.0b013e31817f76f7","volume":"37","author":"VC Ramani","year":"2008","unstructured":"Ramani VC, Haun RS (2008) Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas 37:399\u2013404","journal-title":"Pancreas"},{"key":"9615_CR80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2006.12.018","volume":"249","author":"M Paliouras","year":"2007","unstructured":"Paliouras M, Borgono C, Diamandis EP (2007) Human tissue kallikreins: the cancer biomarker family. Cancer Lett 249:61\u201379","journal-title":"Cancer Lett"},{"key":"9615_CR81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-0-387-98094-2_8","volume-title":"Ovarian cancer","author":"GM Yousef","year":"2009","unstructured":"Yousef GM, Diamandis EP (2009) The human kallikrein gene family: new biomarkers for ovarian cancer. In: Stack MS, Fishman DA (eds) Ovarian cancer. Springer, New York, pp 165\u2013188"},{"key":"9615_CR82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1160\/TH09-01-0026","volume":"101","author":"M Schmitt","year":"2009","unstructured":"Schmitt M, Magdolen V (2009) Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost 101:222\u2013224","journal-title":"Thromb Haemost"},{"key":"9615_CR83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0002-9440(10)63306-8","volume":"165","author":"K Hibbs","year":"2004","unstructured":"Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, Oegema TR Jr, Thiele JJ, Grindle SM, Bliss RL, Skubitz AP (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165:397\u2013414","journal-title":"Am J Pathol"},{"key":"9615_CR84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.20408","volume":"112","author":"AD Santin","year":"2004","unstructured":"Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O\u2019Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112:14\u201325","journal-title":"Int J Cancer"},{"key":"9615_CR85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1160\/TH13-03-0206","volume":"110","author":"J Dorn","year":"2013","unstructured":"Dorn J, Bayani J, Yousef GM, Yang F, Magdolen V, Kiechle M, Diamandis EP, Schmitt M (2013) Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost 110:408\u2013422","journal-title":"Thromb Haemost"},{"key":"9615_CR86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1515\/9783110303667.145","volume-title":"Kallikrein-related peptidases","author":"J Dorn","year":"2012","unstructured":"Dorn J, Milou V, Kulasingam V, Schmalfeldt B, Diamandis EP, Schmitt M (2012) Clinical relevance of kallikrein-related peptidases in ovarian cancer. In: Magdolen V, Sommerhoff C, Fritz H, Schmitt M (eds) Kallikrein-related peptidases. DeGruyter, Berlin, pp 145\u2013166"},{"key":"9615_CR87","first-page":"2380","volume":"7","author":"CV Obiezu","year":"2001","unstructured":"Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, De Rigault La Longrais IA, Arisio R, Diamandis EP (2001) Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7:2380\u20132386","journal-title":"Clin Cancer Res"},{"key":"9615_CR88","first-page":"2372","volume":"7","author":"LY Luo","year":"2001","unstructured":"Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, De Rigault la Longrais IA, Howarth DJ, Diamandis EP (2001) Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7:2372\u20132379","journal-title":"Clin Cancer Res"},{"key":"9615_CR89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0090-8258(03)00257-9","volume":"90","author":"HS Shvartsman","year":"2003","unstructured":"Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC Jr, Gershenson DM, Schmandt R (2003) Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90:44\u201350","journal-title":"Gynecol Oncol"},{"key":"9615_CR90","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2003.09.111","volume":"21","author":"GM Yousef","year":"2003","unstructured":"Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, De Rigault la Longrais IA, Puopolo M, Massobrio M, Diamandis EP (2003) Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 21:3119\u20133126","journal-title":"J Clin Oncol"},{"key":"9615_CR91","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.2004.05.144","volume":"22","author":"A Scorilas","year":"2004","unstructured":"Scorilas A, Borgono CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP (2004) Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 22:678\u2013685","journal-title":"J Clin Oncol"},{"key":"9615_CR92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.11296","volume":"106","author":"CA Borgono","year":"2003","unstructured":"Borgono CA, Fracchioli S, Yousef GM, de Rigault la Longrais IA, Luo LY, Soosaipillai A, Puopolo M, Grass L, Scorilas A, Diamandis EP, Katsaros D (2003) Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer 106:605\u2013610","journal-title":"Int J Cancer"},{"key":"9615_CR93","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1158\/1078-0432.CCR-07-1409","volume":"13","author":"Y Zheng","year":"2007","unstructured":"Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP (2007) A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 13:6984\u20136992","journal-title":"Clin Cancer Res"},{"key":"9615_CR94","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/hsz-2011-0264","volume":"393","author":"L Seiz","year":"2012","unstructured":"Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov NI, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis EP, Langer R, Sweep FC, Schmitt M, Magdolen V (2012) Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem 393:391\u2013401","journal-title":"Biol Chem"},{"key":"9615_CR95","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/IGC.0b013e3181ab597f","volume":"19","author":"E Bandiera","year":"2009","unstructured":"Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A (2009) Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 19:1015\u20131021","journal-title":"Int J Gynecol Cancer"},{"key":"9615_CR96","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/annonc\/mdq462","volume":"22","author":"J Dorn","year":"2010","unstructured":"Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M (2010) Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol 22:877\u2013883","journal-title":"Ann Oncol"},{"key":"9615_CR97","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.2003.02.022","volume":"21","author":"EP Diamandis","year":"2003","unstructured":"Diamandis EP, Scorilas A, Fracchioli S, Van Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D (2003) Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 21:1035\u20131043","journal-title":"J Clin Oncol"},{"key":"9615_CR98","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0009-9120(00)00182-X","volume":"33","author":"EP Diamandis","year":"2000","unstructured":"Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000) Human kallikrein 6 (zyme\/protease M\/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33:579\u2013583","journal-title":"Clin Biochem"},{"key":"9615_CR99","first-page":"807","volume":"63","author":"LY Luo","year":"2003","unstructured":"Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, van der Zee AG, Vergote I, Diamandis EP (2003) The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63:807\u2013811","journal-title":"Cancer Res"},{"key":"9615_CR100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ygyno.2007.01.018","volume":"105","author":"M Shih Ie","year":"2007","unstructured":"Shih Ie M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang Z, Diamandis EP (2007) Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 105:501\u2013507","journal-title":"Gynecol Oncol"},{"key":"9615_CR101","first-page":"893","volume":"11","author":"V Bhan","year":"2004","unstructured":"Bhan V, Mader JS, Hoskin DW (2004) In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells. Oncol Rep 11:893\u2013897","journal-title":"Oncol Rep"},{"key":"9615_CR102","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1158\/0008-5472.CAN-09-3415","volume":"70","author":"Y Dong","year":"2010","unstructured":"Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA (2010) Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 70:2624\u20132633","journal-title":"Cancer Res"},{"key":"9615_CR103","doi-asserted-by":"crossref","first-page":"57056","DOI":"10.1371\/journal.pone.0057056","volume":"8","author":"Y Dong","year":"2013","unstructured":"Dong Y, Stephens C, Walpole C, Swedberg JE, Boyle GM, Parsons PG, McGuckin MA, Harris JM, Clements JA (2013) Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 8:57056","journal-title":"PLoS One"},{"key":"9615_CR104","first-page":"7811","volume":"61","author":"GM Yousef","year":"2001","unstructured":"Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D (2001) Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 61:7811\u20137818","journal-title":"Cancer Res"},{"key":"9615_CR105","first-page":"9032","volume":"63","author":"CA Borgono","year":"2003","unstructured":"Borgono CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth DH, Fracchioli S, Katsaros D, Diamandis EP (2003) Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 63:9032\u20139041","journal-title":"Cancer Res"},{"key":"9615_CR106","first-page":"1153","volume":"11","author":"K Shigemasa","year":"2004","unstructured":"Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O\u2019Brien TJ, Ohama K (2004) Human kallikrein 8 (hK8\/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer. Oncol Rep 11:1153\u20131159","journal-title":"Oncol Rep"},{"key":"9615_CR107","first-page":"1710","volume":"9","author":"Y Dong","year":"2003","unstructured":"Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA (2003) Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 9:1710\u20131720","journal-title":"Clin Cancer Res"},{"key":"9615_CR108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000030150","volume":"22","author":"H Tanimoto","year":"2001","unstructured":"Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, O\u2019Brien TJ (2001) Increased expression of protease M in ovarian tumors. Tumour Biol 22:11\u201318","journal-title":"Tumour Biol"},{"key":"9615_CR109","first-page":"4435","volume":"59","author":"LJ Underwood","year":"1999","unstructured":"Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O\u2019Brien TJ (1999) Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59:4435\u20134439","journal-title":"Cancer Res"},{"key":"9615_CR110","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1515\/BC.2006.138","volume":"387","author":"J Dorn","year":"2006","unstructured":"Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, Diamandis EP, Schmitt M (2006) Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. Biol Chem 387:1121\u20131128","journal-title":"Biol Chem"},{"key":"9615_CR111","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2013.00153","volume":"3","author":"G Leva Di","year":"2013","unstructured":"Di Leva G, Croce CM (2013) The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 3:153","journal-title":"Front Oncol"},{"key":"9615_CR112","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.bjc.6605634","volume":"102","author":"NM White","year":"2010","unstructured":"White NM, Chow TF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, Mankaruous M, Gabril M, Girgis A, Yousef GM (2010) Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 102:1244\u20131253","journal-title":"Br J Cancer"},{"key":"9615_CR113","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1515\/BC.2008.071","volume":"389","author":"TF Chow","year":"2008","unstructured":"Chow TF, Crow M, Earle T, El-Said H, Diamandis EP, Yousef GM (2008) Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem 389:731\u2013738","journal-title":"Biol Chem"},{"key":"9615_CR114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1515\/9783110303667.83","volume-title":"Kallikrein-related peptidases: novel cancer-related biomarkers","author":"Y Dong","year":"2012","unstructured":"Dong Y, Loessner D, Sieh S, Taubenberger A, Fuhrman-Luck RA, Magdolen V, Hutmacher DW, Clements JA (2012) Cellular model systems to study the tumor biological role of kallikrein-related peptidases in ovarian and prostate cancer. In: Magdolen S, Schmitt, Fritz (eds) Kallikrein-related peptidases: novel cancer-related biomarkers. De Gruyter, Berlin, pp 83\u2013110"},{"key":"9615_CR115","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/ijc.22352","volume":"120","author":"R Lim","year":"2007","unstructured":"Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, Quinn MA, Rice GE (2007) Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: nGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer 120:2426\u20132434","journal-title":"Int J Cancer"},{"key":"9615_CR116","doi-asserted-by":"crossref","first-page":"31852","DOI":"10.1074\/jbc.M705190200","volume":"282","author":"H Yoon","year":"2007","unstructured":"Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M (2007) Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem 282:31852\u201331864","journal-title":"J Biol Chem"},{"key":"9615_CR117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1515\/bc.2010.055","volume":"391","author":"N Beaufort","year":"2010","unstructured":"Beaufort N, Plaza K, Utzschneider D, Schwarz A, Burkhart JM, Creutzburg S, Debela M, Schmitt M, Ries C, Magdolen V (2010) Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem 391:581\u2013587","journal-title":"Biol Chem"},{"key":"9615_CR118","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1515\/BC.2006.102","volume":"387","author":"P Prezas","year":"2006","unstructured":"Prezas P, Arlt MJ, Viktorov P, Soosaipillai A, Holzscheiter L, Schmitt M, Talieri M, Diamandis EP, Kruger A, Magdolen V (2006) Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 387:807\u2013811","journal-title":"Biol Chem"},{"key":"9615_CR119","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ygyno.2012.09.001","volume":"127","author":"D Loessner","year":"2012","unstructured":"Loessner D, Quent VM, Kraemer J, Weber EC, Hutmacher DW, Magdolen V, Clements JA (2012) Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol Oncol 127:569\u2013578","journal-title":"Gynecol Oncol"},{"key":"9615_CR120","doi-asserted-by":"crossref","first-page":"8494","DOI":"10.1016\/j.biomaterials.2010.07.064","volume":"31","author":"D Loessner","year":"2010","unstructured":"Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC (2010) Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 31:8494\u20138506","journal-title":"Biomaterials"},{"key":"9615_CR121","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/bm060504a","volume":"7","author":"SC Rizzi","year":"2006","unstructured":"Rizzi SC, Ehrbar M, Halstenberg S, Raeber GP, Schmoekel HG, Hagenmuller H, Muller R, Weber FE, Hubbell JA (2006) Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part II: biofunctional characteristics. Biomacromolecules 7:3019\u20133029","journal-title":"Biomacromolecules"},{"key":"9615_CR122","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1021\/bm049614c","volume":"6","author":"SC Rizzi","year":"2005","unstructured":"Rizzi SC, Hubbell JA (2005) Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes. Part I: Development and physicochemical characteristics. Biomacromolecules 6:1226\u20131238","journal-title":"Biomacromolecules"},{"key":"9615_CR123","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1039\/c3ib20252f","volume":"5","author":"D Loessner","year":"2013","unstructured":"Loessner D, Flegg JA, Byrne HM, Clements JA, Hutmacher DW (2013) Growth of confined cancer spheroids: a combined experimental and mathematical modelling approach. Integr Biol (Camb) 5:597\u2013605","journal-title":"Integr Biol (Camb)"},{"key":"9615_CR124","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1038\/sj.bjc.6600323","volume":"86","author":"LY Luo","year":"2002","unstructured":"Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA (2002) Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer 86:1790\u20131796","journal-title":"Br J Cancer"},{"key":"9615_CR125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ygyno.2004.03.044","volume":"94","author":"Z Xi","year":"2004","unstructured":"Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Trope C, Saatcioglu F (2004) Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol 94:80\u201385","journal-title":"Gynecol Oncol"},{"key":"9615_CR126","first-page":"2388","volume":"57","author":"A Frankel","year":"1997","unstructured":"Frankel A, Buckman R, Kerbel RS (1997) Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 57:2388\u20132393","journal-title":"Cancer Res"},{"key":"9615_CR127","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","volume":"6","author":"AI Minchinton","year":"2006","unstructured":"Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6:583\u2013592","journal-title":"Nat Rev Cancer"},{"key":"9615_CR128","doi-asserted-by":"crossref","first-page":"9163","DOI":"10.1158\/0008-5472.CAN-09-2483","volume":"69","author":"SH Li","year":"2009","unstructured":"Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D (2009) Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res 69:9163\u20139168","journal-title":"Cancer Res"},{"key":"9615_CR129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1074\/mcp.M500140-MCP200","volume":"5","author":"JJ Stewart","year":"2006","unstructured":"Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B (2006) Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5:433\u2013443","journal-title":"Mol Cell Proteomics"},{"key":"9615_CR130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000081102","volume":"25","author":"MC Ghosh","year":"2004","unstructured":"Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis EP (2004) Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 25:193\u2013199","journal-title":"Tumour Biol"},{"key":"9615_CR131","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1074\/jbc.M408132200","volume":"280","author":"IP Michael","year":"2005","unstructured":"Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, Diamandis EP (2005) Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 280:14628\u201314635","journal-title":"J Biol Chem"},{"key":"9615_CR132","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/BC.2006.094","volume":"387","author":"CV Obiezu","year":"2006","unstructured":"Obiezu CV, Michael IP, Levesque MA, Diamandis EP (2006) Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol Chem 387:749\u2013759","journal-title":"Biol Chem"},{"key":"9615_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.20101","volume":"62","author":"M Matsumura","year":"2005","unstructured":"Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS, Nelson PS (2005) Substrates of the prostate-specific serine protease prostase\/KLK4 defined by positional-scanning peptide libraries. Prostate 62:1\u201313","journal-title":"Prostate"},{"key":"9615_CR134","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.bbrc.2008.03.021","volume":"369","author":"VC Ramani","year":"2008","unstructured":"Ramani VC, Haun RS (2008) The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun 369:1169\u20131173","journal-title":"Biochem Biophys Res Commun"},{"key":"9615_CR135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1071-5576(01)00122-8","volume":"8","author":"CA Witz","year":"2001","unstructured":"Witz CA, Montoya-Rodriguez IA, Cho S, Centonze VE, Bonewald LF, Schenken RS (2001) Composition of the extracellular matrix of the peritoneum. J Soc Gynecol Investig 8:299\u2013304","journal-title":"J Soc Gynecol Investig"},{"key":"9615_CR136","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI33775","volume":"118","author":"HA Kenny","year":"2008","unstructured":"Kenny HA, Kaur S, Coussens LM, Lengyel E (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118:1367\u20131379","journal-title":"J Clin Invest"},{"key":"9615_CR137","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","volume":"67","author":"J Symowicz","year":"2007","unstructured":"Symowicz J, Adley BP, Gleason KJ, Johnson JJ, Ghosh S, Fishman DA, Hudson LG, Stack MS (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67:2030\u20132039","journal-title":"Cancer Res"},{"key":"9615_CR138","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","volume":"69","author":"NM Moss","year":"2009","unstructured":"Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS (2009) Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 69:7121\u20137129","journal-title":"Cancer Res"},{"key":"9615_CR139","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/284067a0","volume":"284","author":"LA Liotta","year":"1980","unstructured":"Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67\u201368","journal-title":"Nature"},{"key":"9615_CR140","doi-asserted-by":"crossref","first-page":"15341","DOI":"10.1021\/bi015775e","volume":"40","author":"TK Takayama","year":"2001","unstructured":"Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K (2001) Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40:15341\u201315348","journal-title":"Biochemistry"},{"key":"9615_CR141","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/sj.bjc.6602495","volume":"92","author":"N Ahmed","year":"2005","unstructured":"Ahmed N, Riley C, Oliva K, Rice G, Quinn M (2005) Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 92:1475\u20131485","journal-title":"Br J Cancer"},{"key":"9615_CR142","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjc.6605185","volume":"101","author":"H Chen","year":"2009","unstructured":"Chen H, Hao J, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432\u2013440","journal-title":"Br J Cancer"},{"key":"9615_CR143","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6690278","volume":"79","author":"W Kuhn","year":"1999","unstructured":"Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, Graeff H (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79:1746\u20131751","journal-title":"Br J Cancer"},{"key":"9615_CR144","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2340\/0001555577203206","volume":"77","author":"E Nylander-Lundqvist","year":"1997","unstructured":"Nylander-Lundqvist E, Egelrud T (1997) Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm Venereol 77:203\u2013206","journal-title":"Acta Derm Venereol"},{"key":"9615_CR145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1743-6109.2006.00109.x","volume":"14","author":"S Stadlmann","year":"2006","unstructured":"Stadlmann S, Pollheimer J, Renner K, Zeimet AG, Offner FA, Amberger A (2006) Response of human peritoneal mesothelial cells to inflammatory injury is regulated by interleukin-1beta and tumor necrosis factor-alpha. Wound Repair Regen 14:187\u2013194","journal-title":"Wound Repair Regen"},{"key":"9615_CR146","doi-asserted-by":"crossref","first-page":"8198","DOI":"10.1158\/0008-5472.CAN-07-0607","volume":"67","author":"B Klucky","year":"2007","unstructured":"Klucky B, Mueller R, Vogt I, Teurich S, Hartenstein B, Breuhahn K, Flechtenmacher C, Angel P, Hess J (2007) Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res 67:8198\u20138206","journal-title":"Cancer Res"},{"key":"9615_CR147","first-page":"1","volume":"1755","author":"L Kurlender","year":"2005","unstructured":"Kurlender L, Borgono C, Michael IP, Obiezu C, Elliott MB, Yousef GM, Diamandis EP (2005) A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 1755:1\u201314","journal-title":"Biochim Biophys Acta"},{"key":"9615_CR148","first-page":"697","volume":"387","author":"OL Tan","year":"2006","unstructured":"Tan OL, Whitbread AK, Clements JA, Dong Y (2006) Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? Biol Chem 387:697\u2013705","journal-title":"Biol Chem"},{"key":"9615_CR149","first-page":"3371","volume":"56","author":"XL Liu","year":"1996","unstructured":"Liu XL, Wazer DE, Watanabe K, Band V (1996) Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer research 56:3371\u20133379","journal-title":"Cancer research"},{"key":"9615_CR150","doi-asserted-by":"crossref","first-page":"26075","DOI":"10.1371\/journal.pone.0026075","volume":"6","author":"D Pepin","year":"2011","unstructured":"Pepin D, Shao ZQ, Huppe G, Wakefield A, Chu CW, Sharif Z, Vanderhyden BC (2011) Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One 6:26075","journal-title":"PLoS One"},{"key":"9615_CR151","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/carcin\/22.11.1775","volume":"22","author":"XY Sun","year":"2001","unstructured":"Sun XY, Donald SP, Phang JM (2001) Testosterone and prostate-specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22:1775\u20131780","journal-title":"Carcinogenesis"},{"key":"9615_CR152","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tips.2012.09.005","volume":"33","author":"G Sotiropoulou","year":"2012","unstructured":"Sotiropoulou G, Pampalakis G (2012) Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 33:623\u2013634","journal-title":"Trends Pharmacol Sci"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-013-9615-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-013-9615-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-013-9615-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:00:33Z","timestamp":1688486433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-013-9615-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,17]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["9615"],"URL":"https:\/\/doi.org\/10.1007\/s10585-013-9615-4","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,17]]}}}